Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target : OSR Health

27 Mar 2026

NEW YORK, March 27, 2026 (Newswire.com) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00.

The flash report highlights recent developments related to the Company's non-invasive glucose monitoring technology (Woori IO), including increasing global interest in potential licensing and distribution opportunities.

Key Highlights from the Flash Report:

Global Licensing Interest in Woori IO:

OSRH recently announced interest from multiple regions, including Japan, Korea, India, Israel, and the United States, for its non-invasive glucose monitoring technology. The Company is exploring potential licensing and distribution pathways as part of its broader commercialization strategy.

NDA Signed with Sinopharm:

OSRH has entered into a non-disclosure agreement with Sinopharm, a large Chinese state-owned pharmaceutical and distribution company. The agreement facilitates information exchange related to regulatory, clinical, and commercial pathways for Woori IO within the Chinese diabetes care market.

Additional Validation of Strategic Direction:

The announcement represents a second notable development in recent months, following the previously disclosed licensing term sheet with BCM Europe AG (BCME) for VXM01. Together, these developments support management's ongoing efforts to advance both its therapeutic and medical device platforms.

Potential Near-Term Milestones:

The Company is expected to work toward a definitive agreement with BCME related to the VXM01 licensing structure, which carries a potential milestone value of up to $815 million. The updated deal structure is intended to position OSRH as the primary counterparty.

Positioning for Capital Formation:

Management continues to engage with institutional investors, and the evolving licensing framework may support future capital raising efforts.

Emerging Growth Research notes that while these developments are constructive, risks remain, including the early-stage nature of certain programs, the non-binding status of some agreements, and potential dilution from future financing activities.

For a copy of the full flash report, please visit:

https://emerginggrowth.com/wp-content/uploads/2026/03/OSRH_Flash-Report_03.26.26.pdf

or

https://emerginggrowth.com/profile/osrh/ (on the right side of the page as you scroll down)

About OSR Holdings, Inc.

Founded in 2020 and headquartered in Bellevue, Washington and Gyeonggi-do, South Korea, OSR Holdings, Inc. (Nasdaq:OSRH) is a global healthcare holding company with operations in Korea and Switzerland. The Company has subsidiaries focused on the development of oral immunotherapies for cancer, biologics for degenerative diseases, and non-invasive glucose monitoring technology. OSRH also distributes medical devices and is expanding into 4th party logistics (4PL).

Contact:

Emerging Growth Research
Research@EmergingGrowth.com
www.EmergingGrowth.com

Forward-Looking Statements

This press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Holdings, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that non-binding agreements do not result in definitive transactions, regulatory challenges, and financing constraints.

SOURCE: OSR Holdings, Inc.

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026 OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

List New post

Who is eligible to participate in the Shareholder Loyalty CVR Program?

All shareholders who own OSR Health common stock as of the applicable Record Date are eligible to apply for the Shareholder Loyalty CVR Program. Shareholders must complete the required enrollment process and satisfy the applicable program requirements before Contingent Value Rights (CVRs) are issued.

How do I enroll?

Enrollment is completed by submitting the appropriate application form. U.S. shareholders will need to hold their shares through Direct Registration (DRS) with the Company's transfer agent before enrolling. Non-U.S. shareholders enroll through a separate application process. Full instructions and forms are available on this page.

What happens if I sell my shares?

The Shareholder Loyalty CVR Program is designed to reward long-term ownership. If you sell, transfer, or otherwise dispose of the shares associated with your CVRs before the applicable milestone is achieved, those CVRs will generally terminate and will no longer be eligible to receive additional shares.

Extra shares recieved by reaching are milestones are free to be sold and don't affect future milestone rewards associated with the CVRs from the original shares held on record date.

Do I need to do anything after enrolling?

Once your enrollment has been approved, no further action is generally required. Simply continue to hold your enrolled shares and remain eligible under the terms of the program. If applicable share price milestones are achieved during the program period, eligible U.S. shareholders will receive the corresponding share distributions in accordance with the program terms. Non U.S. shareholders will have to provide a broker attestation on each measurement date to confirm their original shares position.